The U.S. Food and Drug
Administration (FDA) has approved Strattera, judging it safe and effective for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents, and adults.
Strattera is a selective norepinephrine reuptake inhibitor, a class of ADHD treatment that works differently from the other ADHD medications available.
Strattera is the only FDA-approved non-stimulant ADHD medication clinically proven effective for adults.
Strattera is the first non-stimulant medication approved for the treatment of ADHD in children, adolescents, and adults.
Because Strattera is a non-controlled prescription medication, it offers the convenience of phone-in refills and physician samples.
Strattera is an oral capsule and can be taken once or twice a day to provide full-day relief from ADHD symptoms.